|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
108,674,000 |
Market
Cap: |
76.05(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2298 - $2.31 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 707 |
Guru Rank Value : 1.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
816,825 |
816,825 |
Total Buy Value |
$0 |
$0 |
$194,885 |
$194,885 |
Total People Bought |
0 |
0 |
3 |
3 |
Total Buy Transactions |
0 |
0 |
4 |
4 |
Total Shares Sold |
267,396 |
267,396 |
419,842 |
597,458 |
Total Sell Value |
$170,773 |
$170,773 |
$340,560 |
$1,013,893 |
Total People Sold |
5 |
5 |
6 |
9 |
Total Sell Transactions |
10 |
10 |
23 |
42 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Murugan Amar |
EVP, Chief Legal Officer |
|
2024-05-16 |
4 |
S |
$0.62 |
$19,991 |
D/D |
(32,401) |
695,120 |
|
-15% |
|
Nguyen Anhco |
EVP, Chief Sci. & Tech Officer |
|
2024-05-16 |
4 |
S |
$0.62 |
$26,469 |
D/D |
(42,899) |
898,498 |
|
-15% |
|
Henrich Jill |
EVP, Global Head RA & Quality |
|
2024-05-16 |
4 |
S |
$0.62 |
$15,888 |
D/D |
(25,750) |
529,251 |
|
-15% |
|
Hyllengren Eric J |
EVP, CFO |
|
2024-05-16 |
4 |
S |
$0.62 |
$17,676 |
D/D |
(28,648) |
645,671 |
|
-15% |
|
Touchon Pascal |
President and CEO |
|
2024-05-16 |
4 |
S |
$0.62 |
$50,289 |
D/D |
(81,506) |
1,829,146 |
|
-15% |
|
Roncarolo Maria Grazia |
|
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
238,500 |
|
- |
|
Mallik Ameet |
|
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
227,500 |
|
- |
|
Gallagher Carol Giltner |
|
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
629,608 |
|
- |
|
Fust Matthew K |
|
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
259,000 |
|
- |
|
Heiden William K |
|
|
2024-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
359,000 |
|
- |
|
Murugan Amar |
EVP, Chief Legal Officer |
|
2024-03-04 |
4 |
S |
$0.72 |
$7,232 |
D/D |
(10,044) |
727,521 |
|
8% |
|
Touchon Pascal |
President and CEO |
|
2024-03-04 |
4 |
S |
$0.72 |
$17,888 |
D/D |
(24,844) |
1,910,652 |
|
8% |
|
Nguyen Anhco |
EVP, Chief Sci. & Tech Officer |
|
2024-03-04 |
4 |
S |
$0.72 |
$7,737 |
D/D |
(10,746) |
941,397 |
|
8% |
|
Henrich Jill |
EVP, Global Head RA & Quality |
|
2024-03-04 |
4 |
S |
$0.72 |
$2,793 |
D/D |
(3,879) |
555,001 |
|
8% |
|
Hyllengren Eric J |
EVP, CFO |
|
2024-03-04 |
4 |
S |
$0.72 |
$4,810 |
D/D |
(6,679) |
674,319 |
|
8% |
|
Hyllengren Eric J |
EVP, CFO |
|
2024-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
475,000 |
680,998 |
|
- |
|
Murugan Amar |
EVP, Chief Legal Officer |
|
2024-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
475,000 |
737,565 |
|
- |
|
Nguyen Anhco |
EVP, Chief Sci. & Tech Officer |
|
2024-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
675,000 |
952,143 |
|
- |
|
Henrich Jill |
EVP, Global Head RA & Quality |
|
2024-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
450,000 |
558,880 |
|
- |
|
Touchon Pascal |
President and CEO |
|
2024-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,280,000 |
1,935,496 |
|
- |
|
Nguyen Anhco |
EVP, Chief Sci. & Tech Officer |
|
2023-11-16 |
4 |
S |
$0.39 |
$3,445 |
D/D |
(8,856) |
277,143 |
|
-44% |
|
Hyllengren Eric J |
SVP, CFO |
|
2023-11-16 |
4 |
S |
$0.39 |
$4,652 |
D/D |
(11,958) |
205,998 |
|
-44% |
|
Touchon Pascal |
President and CEO |
|
2023-11-16 |
4 |
S |
$0.39 |
$7,939 |
D/D |
(20,409) |
655,496 |
|
-44% |
|
Murugan Amar |
EVP, Chief Legal Officer |
|
2023-11-16 |
4 |
S |
$0.39 |
$3,231 |
D/D |
(8,307) |
257,084 |
|
-44% |
|
Joshi Manher |
EVP, Chief Medical Officer |
|
2023-11-16 |
4 |
S |
$0.39 |
$4,780 |
D/D |
(12,287) |
171,284 |
|
-44% |
|
736 Records found
|
|
Page 1 of 30 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|